NEW YORK, NY / ACCESSWIRE / June 30, 2016 / Natural gas producers have been trending upwards as prices have rallied to near an eight-month high. The United States Natural Gas Fund, LP (NYSE ARCA: UNG) has surged approximately 29.0 percent in the past month. As of June 28th, natural gas prices have risen in 7 of the 10 previous sessions. Natural gas for July delivery recently touched $2.68 a million British thermal units on the New York Mercantile Exchange and has not traded below the $2.00 level since early March. Register with us now for your free membership and gain access to our energy reports at: www.rdinvesting.com.

Natural gas prices are forecasted to continue to rise on increased summer demand. Private weather forecasters MDA Weather Services and Commodity Weather Group LLC have called for unseasonably warm temperatures deep into June.

“For the next few weeks (the gas market is) all going to be about weather and power,” said Richard Soultanian, co-president of energy-consulting firm NUS Consulting Group in New Jersey. “We’ve started the summer season off with a bang. It’s been really hot and humid.”

Chesapeake Energy Corporation (NYSE: CHK)

Get Your Up-To-Date Chesapeake Energy Research Report at www.rdinvesting.com/company/CHK

Chesapeake Energy’s shares gained 3.27 percent to close at $4.42 a share Wednesday. The stock traded between $4.33 and $4.50 on volume of 29.68 million shares traded. The stock appears to be facing some resistance at $4.81 and $5.02 with some support at $4.35 and $3.68. The company reported production averaged approximately 672,400 Barrels of Oil Equivalent (boe) per day in the first quarter of 2016, an increase of 1 percent year-over-year. Chesapeake’s 2016 first quarter revenues declined by 39% year over year, primarily due to a decrease in the average realized commodity prices received for its production. Chesapeake has reiterated its target of $1.2 to $1.7 billion total gross proceeds from asset divestitures by the end of 2016. Shares of Chesapeake Energy have fallen approximately 1.8 percent year-to-date, but have rallied roughly 6.25 percent in the past month.

Devon Energy Corp. (NYSE: DVN)

Get Your Up-To-Date Devon Energy Research Report at www.rdinvesting.com/company/DVN

Devon Energy’s shares increased 1.94 percent to close at $36.69 a share Wednesday. The stock traded between $36.32 and $37.15 on volume of 6.78 million shares traded. The stock appears to be facing some resistance at $39.14 with some support at $36.48 and $34.69. On June 15th, the company announced an agreement to sell its remaining non-core assets in the Midland Basin for $858 million. Devon Energy has raised its full-year 2016 production guidance from core assets to a range of 540,000 to 560,000 Boe per day, up 7,000 Boe from its previous guidance. Shares of Devon Energy have gained approximately 14.7 percent year-to-date and are up roughly 2.2 percent in the past month.

Encana Corp. (NYSE: ECA)

Get Your Up-To-Date Encana Research Report at www.rdinvesting.com/company/ECA

Encana’s shares jumped 4.92 percent to close at $8.10 a share Wednesday. The stock traded between $7.78 and $8.19 on volume of 11.41 million shares traded. The stock appears to be facing some resistance at $8.49 and $8.93 with some support at $7.90 and $7.48. On June 21st, the company announced an agreement to sell its Gordondale assets, which produced an average of 25,200 BOE per day net after-royalty basis during the first quarter of 2016, to Birchcliff Energy Ltd. for CAD$625 million. Shares of Encana have gained approximately 59.5 percent year-to-date and are up roughly 6.3 percent in the past month.

Southwestern Energy Company (NYSE: SWN)

Get Your Up-To-Date Southwestern Energy Research Report at
www.rdinvesting.com/company/SWN

Southwestern Energy shares fell 6.19 percent to close at $13.03 a share Wednesday. The stock traded between $12.70 and $13.60 on volume of 93.27 million shares traded. The stock appears to be facing some resistance at and $13.19 and $14.28 with some support at $11.26 and $9.32. On June 9th, the company announced a deal with Antero Resources Corporation to sell approximately 55,000 net acres in West Virginia for $450 million, which is expected to close in the third quarter of 2016. Shares of Southwestern Energy have gained approximately 83.2 percent year-to-date and are down roughly 0.23 percent in the past month.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 441829

LONDON, UK / ACCESSWIRE / June 30, 2016 / Active Wall St announces its coverage of market signals with highlight on these Top Gainers from Wednesday’s session: TESARO Inc. (NASDAQ: TSRO), PrivateBancorp, Inc. (NASDAQ: PVTB), and MGT Capital Investments, Inc. (NYSE: MGT).

Stock Market Performance

On Wednesday, June 28, 2016, U.S Stock indexes rallied as worries about the outcome of the U.K.’s vote to leave the European Union appeared to ease.

The Dow Jones industrial average gained 284.96 points, or 1.64%, to 17,694.68. The Nasdaq Composite rose 87.38 points, or 1.86% closing at 4,779.25.

And the S&P 500 added 34.68 points, or 1.7%, to 2,070.77. It was the biggest two-day gain for the S&P 500 in the past four month and the benchmark index has recouped more than half of its losses from the two-day equities rout sparked by the British referendum.

Today, AWS is promoting its market signals coverage with emphasis on TSRO, PVTB, and MGT. Get all of our reports for free by signing up to http://www.activewallst.com/register/.

Top Gainers – TESARO

On Wednesday, shares of TESARO Inc. had more than doubled its market cap gaining 108.01% to close at $77.40, after the company announced the successful clinical trial of its product, Niraparib, for treating ovarian cancer.

The trial showed that the drug extended the lives of the patients taking it by increasing the time elapsed between treatment and tumor progression. The 500 participants in the study already had their tumors shrank from other treatments, but niraparib stopped the tumor from growing again. The company intends on submitting a New Drug Application (NDA) with the US Food and Drug Association in the upcoming fourth quarter.

The stock recorded trading volume of 19.08 million shares, which was higher than its three months average volume of 591,990 shares. Tesaro’s shares have advanced 47.94% since the beginning of 2016.

Top Gainers – PrivateBancorp

Shares of PrivateBancorp, Inc. surged 23.27% on Wednesday, after Canadian Imperial Bank of Commerce (NYSE: CM) announced that it has entered into a definitive agreement to acquire PrivateBancorp in a cash and stock deal valued at $3.8 billion.

Canadian Imperial will pay $18.80 in cash and 0.3657 of its common shares for each share of PrivateBancorp. Canadian Imperial is acquiring PrivateBancorp to expand its base in the U.S. The former company had earlier acquired Atlantic Trust, a private wealth-management firm.

A total of 17.12 million shares of PrivateBancorp changed hands during yesterday’s session, significantly higher than the three month average volume of 892,440 shares. Since beginning of 2016, the stock has gained 8.03%.

Canadian Imperial’s shares declined 2.19% to close at $75.42, following the announcement.

Top Gainers – MGT Capital Investments

On Wednesday, shares of MGT Capital Investments, Inc. climbed 23.17% to finish the trading session at $4.04.

MGT Capital Investments announced it has hired the development team of E-Tagged in order to commercialize the E-Tagged mobile device tracking technology. E-Tagged is a cyber-security product designed to detect and identify approaching individuals or motor vehicles by utilizing a proprietary technology that analyses the radio signals broadcast by cell phones. MGT Capital Investments will utilize the E-tagged technology in soon to be released products that secure digital networks and home systems from unauthorized hacking or unwanted intrusions.

A total of 16.64 million share changed hands as compared to the three month average volume of 10.71 million shares. The company’s stock has advanced 48.53% in the last one month, and has rocketed 1656.52% since the beginning of the year.

Additionally in the news, on Monday, MGT Capital Investments announced that it was added as a member of the Russell Microcap Index.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute

SOURCE: Active Wall Street

ReleaseID: 441854

NEW YORK, NY / ACCESSWIRE / June 30, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Atossa Genetics, Inc. (NASDAQ: ATOS).

The report is available here: ATOS Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Atossa is a clinical-stage pharmaceutical company focused on developing novel therapeutics and delivery methods for the treatment of breast conditions, including breast cancer. The company’s current clinical-stage pipeline includes: 1) Intraductal Microcatheters, which deliver locally-administered pharmaceuticals through the breast ducts; as well as 2) Oral Endoxifen, for the treatment of breast cancer patients who are refractory to tamoxifen. Atossa management is also actively evaluating several additional therapeutic candidates for the treatment of breast conditions and/or breast cancer.

Additional highlights from the initiation report are as follows:

Aspire financing to support clinical program development

Atossa recently received commitments from longtime financing partner Aspire Capital for up to $10mn in at-the-market new equity sales over the next 30 months. While the financing will involve the issuance of new common shares, importantly, the deal provides Atossa with discretion over when Aspire will make purchases, and should provide sufficient capital to advance the company’s clinical development into 2017E. With the company’s ongoing “007” Phase 2 clinical study at Columbia University and the planned initiation of a Phase 2 study for oral endoxifen, the commitment should allow management to focus on operational and regulatory execution as well as the further development of its pipeline.

007 Phase 2 study underway; data expected

On the clinical front, in March Atossa began its “007” Phase 2 study for its lead clinical program, which is investigating the delivery of fulvestrant via Atossa’s intraductal microcatheters in patients with DCIS and invasive breast cancer taking place at Columbia University. This study is currently underway, and Atossa expects to be in a position to review data by the end of 2016E. The hope is that the study will show positive safety data and potentially support its view that the localized drug delivery enabled by its intraductal microcatheters will allow for potentially higher drug exposure versus systematically delivered agents. If Atossa is able to show positive data with fulvestrant, it reasons that the company would seek to collaborate with other pharmaceutical companies to test the effectiveness of its intraductal microcatheters with other drugs to improve breast cancer / DCIS treatment. With 60,000 new DCIS patients and 235,000 new breast cancer patients announced each year in the US, and an average cost per dose of fulvestrant of $14,000, there is clearly a large potential market for this program.

Atossa’s second clinical program, oral endoxifen for breast cancer patients who are refractory to tamoxifen, also holds promise. According to comments by management, Atossa expects to seek a 505(b)(2) regulatory pathway for oral endoxifen, leveraging extensive phase 1 and preclinical data, which, if accepted by the FDA, could potentially accelerate its path to commercialization. Oral endoxifen has a large market, estimated at more than $2 billion by Atossa, targeting as many as 500,000 women, who are seeking to prevent a recurrence and/or reduce their risk of breast cancer but for whom tamoxifen is not effective.

Please review important disclosures at www.seethruequity.com.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information, visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 441861

STATEN ISLAND, NY / ACCESSWIRE / June 30, 2016 / Coffee Holding Co., Inc. (Nasdaq: JVA) (“Coffee Holding” or the “Company”) announced today that it has completed its previously announced acquisition of substantially all of the assets of Coffee Kinetics LLC, a Washington limited liability company, doing business as Sonofresco (“Sonofresco”). Founded in 1999, Sonofresco is a manufacturer of commercial table top coffee roasters and a wholesale supplier of green coffee beans. Sonofresco’s customers include retail coffee and home roasting businesses and Sonofresco oversees importers in the Asian, Australian and New Zealand markets. Revenues generated by Sonofresco are split almost equally between sales of roasting machines and sales of unroasted green coffee beans. Jerry Whitfield, the head of Sonofresco, will continue to serve as an advisor to our Sonofresco business.

“We are very excited to have completed the transaction,” said Andrew Gordon, President and CEO of Coffee Holding. “Sonofresco expands our already extensive reach in sales of high end specialty gourmet Arabica coffees by giving us access to Sonofresco’s significant customer base, which will more than double the number of our green coffee customers. In addition, through the synergies of this acquisition, we will be able to offer Sonofresco customers our extensive list of over 90+ specialty Arabica beans which were not available to them before. We intend to expand Sonofresco’s roasting machine sales both domestically and in the overseas market using our highly scalable platform with our established relationships, market reputation and presence and our overall financial capabilities. We intend to vertically integrate Sonofresco’s current business model by offering products complimentary to their table top roasters, such as grinders and espresso machines, in order to give customers a more complete turn-key roasting operation. We expect that this deal will be accretive to both our bottom and top line numbers,” continued Andrew Gordon, President and CEO of Coffee Holding.

About Coffee Holding

Coffee Holding Co., Inc. is a leading integrated wholesale coffee roaster and dealer in the United States and one of the few coffee companies that offers a broad array of coffee products across the entire spectrum of consumer tastes, preferences and price points. Coffee Holding has been a family-operated business for three generations and has remained profitable through varying cycles in the coffee industry and the economy. The Company’s private label and branded coffee products are sold throughout the United States, Canada and abroad to supermarkets, wholesalers, and individually owned and multi-unit retail customers.

Forward Looking Statements

Any statements that are not historical facts contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected synergies and operating results from the Sonofresco acquisition and the Company’s outlook on future operations. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. We have based these forward-looking statements upon information available to management as of the date of this release and management’s expectations and projections about certain future events. It is possible that the assumptions made by management for purposes of such statements may not materialize. Such statements may involve risks and uncertainties, including but not limited to those relating to product demand, pricing, market acceptance, hedging activities, the effect of economic conditions, intellectual property rights, the outcome of competitive products, risks in product development, the results of financing efforts, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made.

Company Contact

Coffee Holding Co., Inc.
Andrew Gordon
President & CEO
718-832-0800

SOURCE: Coffee Holding Co., Inc.

ReleaseID: 441765

RADNOR, PA / ACCESSWIRE / June 30, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP alerts DeVry Education Group, Inc. (NYSE: DV) (“DeVry” or the “Company”) shareholders that a class action lawsuit has been filed against DeVry on behalf of purchasers of the Company’s securities between February 4, 2011 and January 27, 2016, inclusive (the “Class Period”).

Investors who purchased DeVry securities during the Class Period may, no later than July 12, 2016, petition the Court to be appointed as a lead plaintiff representative of the class. For additional information please visit https://www.ktmc.com/new-cases/devry-education-group-inc#join.

DeVry investors who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299-7706 or at info@ktmc.com.

DeVry provides educational services worldwide through a number of subsidiaries, including DeVry University, one of the largest degree-granting higher education systems in the United States.

The shareholder class action complaint alleges that DeVry and certain of its executive officers made a series of false and/or misleading statements and/or failed to disclose to investors, among other things, that: (i) 90% of DeVry University students from a specific year (e.g., graduates from 2011-2016) who were actively seeking employment did not in fact land or obtain new jobs in their field of study within six months of graduation; (ii) 90% of DeVry University students since 1975 who were actively seeking employment did not in fact land or obtain new jobs in their field of study within six months of graduation; (iii) one year after graduation, the average or median salary of DeVry University graduates with bachelor’s degrees was not in fact 15% higher than the average or median salary of graduates with bachelor’s degrees from all other colleges and universities; and (iv) DeVry overstated its growth, revenue, and earnings potential by concealing the true employment prospects of DeVry University graduates to investors and potential students.

On January 27, 2016, the Federal Trade Commission (“FTC”) filed suit against DeVry and DeVry University accusing them of deceptively advertising the benefits of obtaining a bachelor’s degree at DeVry University. Also on January 27, 2016, the U.S. Department of Education issued DeVry University a Notice of Intent to Limit its participation in programs authorized pursuant to Title IV of the Higher Education Act of 1965, after finding that DeVry was in violation of federal law.

Following this news, shares of DeVry common stock declined $3.65 per share, or over 15%, to close on January 27, 2016 at $20.09 per share, on unusually heavy trading volume.

Members of the class may, no later than July 12, 2016, petition the Court to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, or for additional information about participating in this action, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
Darren J. Check, Esq.
D. Seamus Kaskela, Esq.
Adrienne O. Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 441612

NEW YORK, NY / ACCESSWIRE / June 30, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of CytoDyn Inc. (OTCQB: CYDY).

The report is available here: CYDY Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Based in Vancouver, WA, CytoDyn is engaged in the development of humanized monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV), and other diseases. CytoDyn’s lead drug candidate is PRO-140, a viral entry inhibitor which seeks to block HIV from entering a cell by binding to a molecule called CCR5. CytoDyn has a Phase 3 clinical trial underway with PRO-140 for HIV in combination with Highly Active Anti-Retroviral Therapy (HAART). The company also recently initiated a Phase 3 trial of PRO-140 for long-term monotherapy as a replacement for HAART for patients who have completed initial antiretroviral therapy (ART). If approved, PRO-140 would be the first, self-administered, injectable antibody therapy for HIV. Indeed, whether approved as a combination therapy or first line therapy, PRO-140 promises to be a significant advancement in the treatment of HIV, which could dramatically improve the quality of life for HIV patients while sharply lowering toxicity, offering fewer side-effects, and lowering costs versus existing treatments.

Additional highlights from the initiation report are as follows:

PRO-140 promised to be a highly differentiated approach to HIV

Core to CytoDyn’s value proposition is PRO-140, which is the company’s lead clinical candidate for the treatment and prevention of HIV, and potentially other autoimmune diseases. PRO-140 is a viral-entry inhibitor designed to protect healthy cells from viral infection. Specifically, PRO-140 is a self-administered, injectable humanized monoclonal antibody which seeks to prevent HIV entry into white blood cells by binding to the CCR5 co-receptor on white blood cells. CCR5 is the predominant HIV (R5) subtype entry into T-cells, accounting for 70% of HIV-infected Americans and 90% of those newly dosed, which would make PRO-140 a potential therapeutic option to a significant portion of the HIV patient population. Indeed, management estimates that the potential pool of HIV patients that might be applicable for PRO-140 if it is approved as a combination therapy or monotherapy replacing HAART would be 207,000 or 460,000 per year, respectively. CytoDyn recently presented positive data from a Phase 2b clinical trial extension of PRO-140, in which the company stated that weekly PRO-140 subcutaneous 350mg treatments administered to HIV patients for over a year and a half were well-tolerated and provided full viral suppression.

Initiate coverage with a price target of $3.40

We see CytoDyn as a speculative company in the biotechnology sector, with the potential to introduce and commercialize an impactful new therapy with the potential to dramatically improve the lives of many people living with HIV. We see several key events on the horizon for CytoDyn as it advances its lead drug candidate technology PRO-140 in Phase 3 clinical trials for the treatment of HIV in both as a combination treatment with the current standard of care as well as a monotherapy. Collectively these represent more than a $15 billion market opportunity for CytoDyn and if PRO-140 is approved by the FDA it would likely be a significant new entry to the market. Indeed, PRO-140 promises lower costs, lower toxicity, fewer side effects and an improvement in lifestyle versus the current standard of care given the advantages of a long-acting subcutaneous, self-administered injection versus a cumbersome daily pill regimen. If achieved, the price target of $3.40 suggests potential upside of 211.9% from the recent price of $1.09 on June 28, 2016.

Please review important disclosures at www.seethruequity.com.

About CytoDyn Inc.

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several weeks of interruption from conventional drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV indications where CCR5 and its ligand CCL5 may be involved. For more information on the Company, please visit www.cytodyn.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information, visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 441860

FOSTER CITY, CA / ACCESSWIRE / June 30, 2016 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) (“Aoxing Pharma”), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that it has started commercial production of Tilidine Hydrochloride tablets, a narcotic drug product. This is a significant milestone for the Company.

“The start of production of Tilidine tablet suggests that Aoxing’s capability in research and development has been recognized by the CFDA (China Food and Drug Administration),” said Mr. Zhenjiang Yue, Chairman and CEO of Aoxing Pharma. “We believe that the new products in our R&D programs, including other narcotic drugs, addiction treatment, weight loss treatment, and mental health-related pharmaceutical drugs, should become drivers for growth in the future. These achievements are the results of the hard work of our management team and all of our employees. We appreciate both the strong support and patience of our shareholders.”

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has one of the most advanced manufacturing facilities in China for highly regulated narcotic medicines.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.

Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. Undue reliance should not be placed on forward-looking information. The economic, competitive, governmental, technological and other risk factors identified in the Company’s filings with the Securities and Exchange Commission, specifically, Item 1A, “Risk Factors,” in the Form 10-K for the year ended June 30, 2014, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

CONTACT:

Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com

SOURCE: Aoxing Pharmaceutical Company, Inc.

ReleaseID: 441847